Trabectedin (Yondelis) is a new type of alkylating agent, indicated for patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously received anthracycline-containing regimens. Due to the drug’s strict usage contraindications and complex adverse reaction management system, standardized access channels are crucial for ensuring its therapeutic efficacy.

How to Purchase Trabectedin (Yondelis)

Overseas Purchase

Patients may choose to visit hospital pharmacies or legitimate drugstores in countries or regions where trabectedin has been launched to consult and purchase the drug.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budgets and plans in advance before purchasing.

Purchase through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Using Trabectedin (Yondelis)

Monitoring of Hematologic Toxicity

43% of patients experience grade 3–4 neutropenia, and 2.6% develop neutropenic sepsis, of which 1.1% result in death.

Neutrophil count must be tested before each dose administration; treatment should be suspended if the count is below 1500/mcL.

Protection of Organ Function

Hepatotoxicity: 35% of patients develop grade 3–4 liver function abnormalities, and 18% experience ALT/AST elevation exceeding 8 times the upper limit of normal. Regular monitoring of transaminase and bilirubin levels is required.

Cardiomyopathy: 6% of patients develop cardiomyopathy, 4% of which are grade 3–4. Patients with baseline LVEF below the lower limit of normal, cumulative anthracycline dose ≥ 300 mg/m², age ≥ 65 years, or a history of cardiovascular disease are at higher risk.

Management of Contraindications

Active urinary retention or gastric retention.

Untreated angle-closure glaucoma.

Hypersensitivity to trabectedin or any of its components.

Severe hepatic impairment.

Identification of Trabectedin (Yondelis) Authenticity

Verification of Packaging Markings

Authentic products are packaged in glass vials.

NDC code (59676 series) and complete batch number information.

Storage requirement: refrigeration at 2°C–8°C.

Identification of Physical Properties

The lyophilized powder is white to off-white in color.

The reconstituted solution is clear, colorless to pale tan.

Each vial contains 1 mg of trabectedin, 27.2 mg of potassium dihydrogen phosphate, and 400 mg of sucrose.